CTRI/2011/10/002073已完成3 期
Single-dose, multicenter, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of oral palonosetron 0.50 mg compared to I.V. palonosetron 0.25 mg administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapy.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 740
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female patient >=18 years of age.
- •2.Naive to cytotoxic chemotherapy. Previous biological or hormonal therapy is permitted.
- •3.Diagnosed with a malignant solid tumor and scheduled to receive first course of cytotoxic chemotherapy with cisplatin administered as a single I.V. dose of 70 mg/m2 over 1-4 hours on study Day 1, either alone or in combination with other chemotherapeutic agents ( If scheduled to receive combination regimens, non-cisplatin agents of moderate to high emetogenic potential are allowed and they must be administered following the cisplatin infusion and completed no more than 6 hours after the initiation of cisplatin infusion; If scheduled to receive chemotherapy agents of minimal to low emetogenic potential, they are to be given on Day 1 following cisplatin or on any subsequent study day).
- •4.ECOG Performance Status of 0, 1, or 2 (Appendix 4).
- •5.Hematologic and metabolic status adequate for receiving a highly emetogenic
- •6.cisplatin-based regimen.
- •7.Able to read, understand, follow the study procedure and complete patient diary.
排除标准
- •1.If female, pregnant or lactating.
- •2.Current use of illicit drugs or current evidence of alcohol abuse.
- •3.Scheduled to receive moderately emetogenic chemotherapy (MEC) or HEC
- •4.from Day 2 to Day 5 following cisplatin administration.
- •5.Received or is scheduled to receive radiation therapy to the abdomen, or the pelvis within 1 week prior to Day 1 or between Days 1 to 5.
- •6.Any vomiting, retching, or mild nausea within 24 hours prior to Day 1.
- •7.Symptomatic primary or metastatic CNS malignancy.
- •8.Active peptic ulcer disease, gastrointestinal obstruction, increased intracranial pressure, hypercalcemia, an active infection or any uncontrolled medical conditions (other than malignancy) that, in the opinion of the investigator, may confound the results of the study, represent another potential etiology for emesis and nausea (other than chemotherapy-induced nausea and vomiting, CINV) or pose unwarranted risks in administering the study drugs to the patient.
- •9.Known hypersensitivity or contraindication to 5-HT3 receptor antagonists (e.g., palonosetron, ondansetron, granisetron, dolasetron, tropisetron, ramosetron) or dexamethasone.
- •10.Systemic corticosteroid therapy at any dose within 72 hours prior to Day 1. However topical and inhaled corticosteroids with a steroid dose of 10 mg of prednisone daily or its equivalent are permitted.
- •11.Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy.
- •12.Any medication with known or potential antiemetic activity within 24 hours prior to Day 1
- •13.Any illness or condition that, in the opinion of the investigator, may confound the results of the study or pose unwarranted risks in administering the investigational product to the patient.
- •14.Concurrent medical condition that would preclude administration of dexamethasone for 4 days such as systemic fungal infection or uncontrolled diabetes.
研究者
相似试验
进行中（未招募）
不适用
Single-dose, multicenter, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of oral palonosetron 0.50 mg compared to I.V. palonosetron 0.25 mg administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapyEUCTR2010-022223-29-HUHelsinn Healthcare SA750
进行中（未招募）
不适用
PALO-10-01 is a clinical study assessing efficacy and safety of a single oral dose of palonosetron 0.50 mg compared to a single intravenous dose of palonosetron (Aloxi, an antiemetic drug), both given with oral dexamethasone. The study aims to demonstrate that palonosetron 0.50 mg given orally is as effective and safe as palonosetron 0.25 mg given intravenously to prevent nausea and vomiting in the first 24 hours after administration of one cycle of highly emetogenic cancer chemotherapyausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapyMedDRA version: 14.1Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-022223-29-DEHelsinn Healthcare SA750
进行中（未招募）
不适用
Single-dose, multicenter, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of oral palonosetron 0.50 mg compared to I.V. palonosetron 0.25 mg administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapy. - NDausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapyMedDRA version: 13.1Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-022223-29-ITHelsinn Healthcare SA750
进行中（未招募）
不适用
PALO-10-01 is a clinical study assessing efficacy and safety of a single oral dose of palonosetron 0.50 mg compared to a single intravenous dose of palonosetron (Aloxi, an antiemetic drug), both given with oral dexamethasone. The study aims to demonstrate that palonosetron 0.50 mg given orally is as effective and safe as palonosetron 0.25 mg given intravenously to prevent nausea and vomiting in the first 24 hours after administration of one cycle of highly emetogenic cancer chemotherapyausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapyMedDRA version: 14.1Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-022223-29-BGHelsinn Healthcare SA750
进行中（未招募）
不适用
PALO-10-01 is a clinical study assessing efficacy and safety of a single oral dose of palonosetron 0.50 mg compared to a single intravenous dose of palonosetron (Aloxi, an antiemetic drug), both given with oral dexamethasone. The study aims to demonstrate that palonosetron 0.50 mg given orally is as effective and safe as palonosetron 0.25 mg given intravenously to prevent nausea and vomiting in the first 24 hours after administration of one cycle of highly emetogenic cancer chemotherapyausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapyMedDRA version: 14.1Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-022223-29-PLHelsinn Healthcare SA750